Leveraging CRISPR Arrayed Screens to Validate & De-Risk Targets Through Off-Target Reduction
- Exploring how CRISPR arrayed screens can be designed and deployed to identify and validate novel targets, giving you a scalable framework for accelerating early discovery
- Examining how validated CRISPR screen hits are assessed for pipeline fit across autoimmune disease indications, helping you strengthen your own target selection criteria
- Discussing strategies to minimize off-target effects during target identification screening, equipping you with optimized guide RNA and high-fidelity Cas9 approaches to improve hit confidence